New hope for Prader-Willi: drug targets uncontrollable hunger
NCT ID NCT07266324
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called BMB-101 in 16 adults with Prader-Willi syndrome who struggle with severe, constant hunger. The trial is double-blind and placebo-controlled, meaning some participants get the drug and some get a dummy treatment, and neither they nor their doctors know who gets what. The main goal is to see if BMB-101 safely reduces hyperphagia (extreme hunger) and improves daily life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRADER-WILLI SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alfred Health
Melbourne, Victoria, 3004, Australia
-
Royal Prince Alfred Hospital
Sydney, New South Wales, 2050, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can early parent coaching help infants with rare genetic disorders thrive?
- Newborn screening study aims to catch rare diseases at birth
- Brain and eye clues to emotion recognition in autism and psychosis
- New group therapy aims to tame meltdowns in Prader-Willi teens
- CBDV study for Prader-Willi syndrome halted early
- Can a light box beat daytime sleepiness in Prader-Willi?